KPNA2 and lung carcinoma: The knockdown of KPNA2, one of the neoantigen-presenting CAF-specific markers, attenuated CAF invasiveness, suggesting that CAF subtype markers may represent therapeutic targets within the tumor microenvironment of lung cancer patients.